Related Experiment Video
Updated: May 11, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Normal cognition in transgenic BRI2-Aβ mice
Jungsu Kim1, Paramita Chakrabarty, Amanda Hanna
1Department of Neuroscience and Center for Translational Research in Neurodegenerative Disease, University of Florida, 1275 Center Drive, Gainesville, FL 32610, USA.
Molecular Neurodegeneration
|May 14, 2013
Summary
High levels of amyloid-beta peptides alone do not cause cognitive decline in mice. This suggests amyloid precursor protein (APP) overexpression or its derivatives may be key drivers of memory deficits in Alzheimer's disease models.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) research implicates amyloid-beta (Aβ) in cognitive impairment.
- Transgenic mouse models overexpressing amyloid precursor protein (APP) exhibit AD-like pathology and cognitive deficits.
Purpose of the Study:
- To investigate the cognitive impact of Aβ peptides produced independently of APP overexpression.
- To examine the BRI2-Aβ transgenic mouse model for Aβ-mediated cognitive impairment.
Main Methods:
- Utilized BRI2-Aβ transgenic mice producing extracellular Aβ1-40, Aβ1-42, or both.
- Assessed cognitive performance using established behavioral tests.
- Compared cognitive function pre and post amyloid plaque formation.
Main Results:
- BRI2-Aβ1-42 mice showed intact cognitive performance despite amyloid pathology.
- Mice producing Aβ1-40 or both Aβ peptides also exhibited normal cognition.
- No memory deficits were observed in BRI2-Aβ models.
Conclusions:
- Elevated Aβ1-40 or Aβ1-42 alone does not replicate memory deficits seen in APP transgenic models.
- APP overexpression or its processing derivatives may be critical for cognitive decline.
- The BRI2-Aβ model may not fully recapitulate Aβ's cognitive impact mechanisms.
